Income Taxes (Narrative) (Details) - USD ($)		12 Months Ended
		Sep. 30, 2016	Sep. 25, 2015	Sep. 26, 2014	Aug. 31, 2016	Feb. 01, 2016
Income Taxes [Line Items]
Operating loss carryforward			$ 7,000,000	$ 221,300,000
Tax credit carryforward			11,200,000	8,600,000
Tax Credit Carryforward Utilization		$ 12,400,000	14,300,000
Income Tax Holiday, Aggregate Dollar Amount		1,000,000	5,100,000	300,000
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	[1],[2]	$ (249,300,000)	$ (152,900,000)	$ (14,200,000)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		20.00%	20.00%	35.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount				$ 19,000,000.00
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent				21.00%
Increase (Decrease) Tax Benefit, Jurisdiction Rate Difference		$ 96,400,000	$ 138,700,000
Increase (Decrease) Tax Expense (Benefit), Change in Operating Income		146,300,000	62,400,000
Increase (Decrease) Tax Expense (Benefit) Due to Amortization of Intangible Assets		56,800,000	22,500,000
Increase (Decrease) Foreign Tax Expense (Benefit) Due To Acquisitions		32,000,000	62,200,000
Increase (Decrease) Tax Expense (Benefit), Other		25,100,000	31,800,000
Income Tax Benefit from Change in Rate from Domestic to Foreign			4,800,000
Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate		113,100,000	87,400,000	$ 82,000,000
Interest expense on unrecognized tax benefits		4,100,000	5,700,000	7,000,000
Released tax interest		32,100,000
Increase (Decrease) in Unrecognized Tax Benefits Interest, Discontinued Operations		6,500,000
Interest accrued on unrecognized tax benefits		7,200,000	41,700,000	45,100,000
Decrease in Unrecognized Tax Benefits is Reasonably Possible		14,600,000
Income tax penalties and interest accrued that would impact effective tax rate, upper bound of change		6,100,000
Tax payments associated with non-current deferred intercompany transactions		69,100,000	51,700,000
Income Tax Receivable, Deferred Intercompany Transactions			81,100,000
Tax payments associate with current deferred intercompany transactions		10,000,000	8,700,000
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority		43,500,000
Deferred income taxes		0	139,200,000
Deferred income taxes (non-current liability)		2,581,400,000	3,117,500,000
Deferred Tax Liabilities, Net		2,557,300,000	2,975,900,000
Increase (Decrease), Deferred Tax Liability Due to Amortization of Intangible Assets		66,400,000
Increase (Decrease), Deferred Tax Liability, Other		(50,000,000)
Increase (Decrease), Deferred Tax Liability, Recent Acquisitions		(25,700,000)
Deferred tax assets, tax credit carryforwards		332,300,000	159,500,000
Deferred tax assets, valuation allowance		564,900,000	233,000,000
Increase (decrease) deferred tax liability due to installment sale		1,902,900,000	1,465,300,000
Increase (decrease) deferred tax asset resulting from installment sale transaction		322,800,000
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		122,600,000
Deferred tax liabilities, intangible assets		775,100,000	1,550,700,000
Deferred Tax Liabilities, Property, Plant and Equipment		111,300,000	111,800,000
Deferred Tax Asset, Financing Payment		14,900,000	8,700,000
Tax credit carryforwards, not subject to expiration			4,000,000
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries			354,800,000
Hemostasis Products
Income Taxes [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign						$ 23,000,000
Increase (Decrease) in Deferred Tax Liability, Intangible Assets		(20,300,000)
Deferred Tax Liabilities, Inventory						$ 4,100,000
Increase (Decrease), Deferred Tax Liability, Net		1,400,000
Ikaria
Income Taxes [Line Items]
Operating loss carryforward			4,800,000
Tax credit carryforward			7,200,000
Increase (decrease) deferred tax asset resulting from installment sale transaction		519,500,000
Increase (Decrease) in Income Taxes		42,800,000
Increase (Decrease) in Deferred Charges		23,800,000
Increase (Decrease) in Prepaid Taxes		1,000,000
Increase (Decrease) in Deferred Tax Liability, Intangible Assets		535,100,000
Therakos
Income Taxes [Line Items]
Increase (decrease) deferred tax asset resulting from installment sale transaction		250,400,000
Increase (Decrease) in Income Taxes		17,300,000
Increase (Decrease) in Prepaid Taxes		300,000
Increase (Decrease) in Deferred Tax Liability, Intangible Assets		267,300,000
Cadence Pharmaceuticals, Inc.
Income Taxes [Line Items]
Operating loss carryforward				187,800,000
Stratatech [Member]
Income Taxes [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign					$ 11,200,000
Increase (Decrease) in Deferred Tax Liability, Intangible Assets		(35,500,000)
Increase (Decrease), Deferred Tax Liability, Net		24,300,000
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating loss carryforward		1,000,000
Internal Revenue Service (IRS)
Income Taxes [Line Items]
Advance payment in connection with proposed settlements of certain tax matters			8,900,000
Advance payment in connection with proposed settlement of certain tax matters, tax payment			7,400,000
Advance payment in connection with proposed settlement of certain tax matters, interest payment			1,500,000
Internal Revenue Service (IRS) | Covidien
Income Taxes [Line Items]
Advance payment in connection with proposed settlements of certain tax matters				35,900,000
Advance payment in connection with proposed settlement of certain tax matters, tax payment				27,300,000
Advance payment in connection with proposed settlement of certain tax matters, interest payment				8,600,000
U.S. - Federal and State
Income Taxes [Line Items]
Operating loss carryforwards, subject to expiration			$ 75,000,000
IRELAND
Income Taxes [Line Items]
Tax years that remain subject to examination			2009
Foreign Tax Authority
Income Taxes [Line Items]
Operating loss carryforward		29,200,000
Tax Credit Carryforward Utilization		9,500,000
Operating loss carryforwards			$ 246,100,000
Operating loss carryforwards, not subject to expiration			175,300,000
Operating loss carryforwards, subject to expiration			70,800,000
Foreign Tax Authority | Hemostasis Products
Income Taxes [Line Items]
Operating loss carryforward		17,900,000
Discontinued Operations, Held-for-sale
Income Taxes [Line Items]
Deferred Tax Liabilities, Undistributed Foreign Earnings		3,900,000	6,500,000
Undistributed Earnings			$ 41,300,000
Contrast Media and Delivery Systems
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount				$ 3,000,000
Increase (Decrease) Net Operating Loss		$ 29,500,000
Latest Tax Year [Member] | U.S. - Federal and State
Income Taxes [Line Items]
Tax years that remain subject to examination		2010
Earliest Tax Year [Member] | U.S. - Federal and State
Income Taxes [Line Items]
Tax years that remain subject to examination		2000

[1] Due to the December 31, 2013 Research Credit tax law expiration, fiscal 2014 includes $0.7 million for the period September 28, 2013 through December 31, 2013. During fiscal 2015, the legislation was extended, with a retroactive effective date of January 1, 2014. As such, fiscal 2015 includes approximately $3.6 million of credit related to the period January 1, 2014 through September 26, 2014.

[2] Includes the impact of certain recurring valuation allowances for Domestic and International jurisdictions.